Driving the Next Generation of Oncology Diagnostics & Therapeutics

Thursday 28th of April, 2022

6:00 pm Registration & Welcome Reception

6:30 pm Opening Remarks & Introduction

6:35 pm Actioning the Genome Through Entrepreneurship & Start-Ups

  • Bobby Kaura Director, Illumina for Start-Ups, Global Ecosystem Development, Illumina

Synopsis

• Open Innovation – Partnering with Pharma and Biotech
• An overview of Illumina for Start-ups – Creating genomic VC backable companies
• What it takes to be a backable VC company and examples of pioneering Start-ups

6:45 pm Developing a Pan-Cancer Precision Therapeutics Platform

Synopsis

• Using chromosomal instability to target pan-cancer populations
• Our strategic approach to platform validation
• How we view partnership opportunities for CDx and therapeutics as a startup

6:55 pm On the Path to Leaving No Eligible Patient Behind: Choosing the Right Diagnostic Partner to Enable Broader Patient Access to the Right Therapeutics

  • Flora Berisha Head of Dx Strategic Partnering, Oncology, Janssen, Global R&D

Synopsis

• The importance of strategic partnerships for long-term strategic growth
• How to identify the right strategic partner
• Jansen’s precision medicine strategy for Oncology

7:05 pm Shaping the Future of Clinical Next Generation Sequencing Testing in Oncology

  • Megan Townsend Business Development Manager, CDx Partnerships, Illumina

Synopsis

• Illumina’s CDx Vision: Building a single CGP/CDx solution for all market
• The path forward to evolve testing infrastructure and gain broad patient access
• Building strategic partnerships to evolve and grow a changing healthcare landscape

7:15 pm Interactive Panel Discussion & Q&A: Driving the Next Generation of Oncology Diagnostics & Therapeutics: We Cannot Do It Alone

  • Bobby Kaura Director, Illumina for Start-Ups, Global Ecosystem Development, Illumina
  • Jason Yip Co-Founder , Tailor Bio
  • Megan Townsend Business Development Manager, CDx Partnerships, Illumina
  • Flora Berisha Head of Dx Strategic Partnering, Oncology, Janssen, Global R&D

Synopsis

• The latest biomarker and CDx strategies to guarantee broader patient adoption of oncology therapeutics across the globe
• How biopharma is integrating NGS into clinical development to achieve long-term strategic stability and clinical success in oncology therapeutic development
• How Illumina is working to bridge the different ecosystems across the cancer care continuum, from early innovation, clinical development, and patient care to drive the latest innovative concepts into marketable therapeutics and diagnostics, and to deliver future proof CDx solutions to biopharma’s oncology pipelines

 

7:40 pm Networking & Drinks

Synopsis

This is an informal and exclusive networking opportunity for you to engage with companies who share your goal in improving health outcomes in oncology and to identify potential routes to partner and support one another!

8:30 pm End of Illumina Engager